Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study

Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)

(2014) Tsutomu Takeuchi et al.   Modern Rheumatology

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

(2012) Jacqueline Detert et al.   ANNALS OF THE RHEUMATIC DISEASES

Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis

(2012) Yoshiya Tanaka   CURRENT OPINION IN RHEUMATOLOGY

Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis

(2012) Kalle J. Aaltonen et al.   PLoS One

Do anti-TNF-α drugs increase cancer risk in rheumatoid arthritis patients?

(2012) David A. Clark   INFLAMMOPHARMACOLOGY

Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies

(2011) Anna K. Wong et al.   CLINICAL RHEUMATOLOGY

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study

(2010) Y. Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor

(2009) Zehra Kaymakcalan et al.   CLINICAL IMMUNOLOGY

Differences in binding and effector functions between classes of TNF antagonists

(2009) Taruna Arora et al.   CYTOKINE

Mechanisms for cytotoxic effects of anti–tumor necrosis factor agents on transmembrane tumor necrosis factor α–expressing cells: Comparison among infliximab, etanercept, and adalimumab

(2008) Hiroki Mitoma et al.   ARTHRITIS AND RHEUMATISM